Latest News about Cybin
Recent news which mentions Cybin
Cybin: Positive Data Announced From Innovative Drug Trial
March 02, 2023
From Benzinga
Cybin: Psychedelic Based BioPharma Company To Announce Much Anticipated Updates For Its Ongoing Clinical Trials
February 27, 2023
From Benzinga
Cybin Approved For First In-Human Dosing Of DMT Molecule CYB004, Milestone For Anxiety Disorder Treatment
February 01, 2023
From Benzinga
From Benzinga
BREAKING: Cybin And Clinilabs Receive DEA License For First-In-Human Clinical Trial Of Psilocybin To Treat Depression
August 17, 2022
From Benzinga
From Benzinga
How Does Ketamine Affect The Brain Over Time?
June 25, 2022
From Benzinga
Cybin Presents "Why Cybin Is Investing So Heavily On Developing Novel Psychedelic Molecules" At The Psychedelic Capital Conference
April 25, 2022
Tickers
CYBN
From Benzinga
Cybin's Major Depressive Disorder Treatment Trials Continue With Clinilabs Drug Development Corp
April 22, 2022
Tickers
CYBN
From Benzinga
From Benzinga
Cybin Begins Study Using Kernel Flow Headsets To Measure Ketamine's Effects On The Brain
March 31, 2022
Tickers
CYBN
From Benzinga
From Benzinga
Cybin Reports Q2 Financial Results And Latest News, Including FDA & DEA Research Approvals
November 15, 2021
Tickers
CYBN
From Benzinga
Cybin Announces Positive Data Showing Effectiveness of Psilocybin To Treat Depression
November 08, 2021
Tickers
CYBN
From Benzinga
Cybin: FDA Authorizes Feasibility Study To Measure Ketamine's Effect On Cerebral Cortex
October 27, 2021
Tickers
CYBN
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.